UPDATE 1-ABCAM sees FY pretax 9 pct ahead of consensus

* Profits boosted by cost control

* Sales ahead of expectations due to exchange rates (Adds details)

LONDON, July 15 (Reuters) - British antibody supplier Abcam (ABCA.L) said on Wednesday it sees full-year pretax profit coming in about 9 percent ahead of market expectations as it benefits from favourable currency and cost control.

In an end of year management statement it said trading in the second half of the year was strong and the exchange rate environment was more favourable than previously envisaged.

The company is expected to book full-year pretax profit before exceptional items of 14.4 million pounds ($23.43 million), according to a consensus of 5 analysts polled by Reuters.

(Reporting by Ben Deighton)